Scientists at St. Jude Children’s Research Hospital developed a simple method to select for more effective cancer-destroying CAR T cells for patients with relapsed T-ALL. Scientists at St. Jude Children’s Research Hospital are improving chimeric antigen receptor (CAR) T-cell therapy. Their new simplified approach selected for an advantageous T-cell type and showed promise in the lab against relapsed T-cell
CNS relapse is still a common cause of treatment failure in R/R B-ALL, although chemotherapy, cranial irradiation, and allo-HSCT are all modalities that can be incorporated into the management of CNSL. In the present study, published on Blood by a team of Xuzhou Medical University, was reported the efficacy, toxicity, and clinical feasibility of CD19-specific
Stanford researchers modified anti-cancer CAR-T cells so they can be controlled with an oral drug. The modified cells are safer, more potent and more active against solid tumors in mice. A cancer treatment that uses a patient’s own genetically modified immune cells to attack cancer cells is safer and more effective when it can be
Chimeric antigen receptor T-cell therapy, or CAR T, has made a big impact on the treatment of certain blood cancers, allowing patients with relapsed/refractory disease to live longer, healthier lives. But in clinical study, the cellular therapy has not been as successful for patients with solid tumors, due in part to the lack of tumor
Key Takeaways Acute myeloid leukemia is the most common leukemia in adults. CAR T cell therapy has made significant inroads against leukemias and lymphomas arising from B cells, but have been largely ineffective against leukemias arising from myeloid cells. MGH investigators have devised a novel method for improving CAR T therapy through a drug combination
On April 1, 2022, the Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma. Approval was
A MRNA VACCINE WAS COMBINED WITH CAR T CELLS THAT TARGET TUMOR CELLS EXPRESSING THE CLDN6 ANTIGEN A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data
CD19 CAR T-cell therapy is effective at achieving durable remission for relapsed/refractory ALL across cytogenetic risk groups. CD19 CAR T-cell treatment results for patients with high-risk cytogenetics including Ph+, Ph-like, and KMT2A-rearranged ALL are encouraging. Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions of relapsed/refractory B-acute lymphoblastic leukemia (ALL). However, case reports suggested differential
Immunotherapy is increasingly becoming a successful way to treat cancer. Researchers at Uppsala University have now developed armed CAR-T cells that reinforce the immune defense against cancer and that could increase the possibilities to successfully treat solid tumors. The study has been published in the journal Nature Biomedical Engineering. The use of immunotherapy to treat cancer
A new approach allowed scientists to alter immune cells within 24 hours versus the standard of up to two weeks A new approach from Penn Medicine researchers could cut the time it takes to alter patients’ immune cells for infusion back into the body to find and attack cancer. The cell manufacturing process for this type of
